CA2135748A1 - Methodes et agents servant a la modulation de la reaction immunitaire, et utilisation de ceux-ci - Google Patents

Methodes et agents servant a la modulation de la reaction immunitaire, et utilisation de ceux-ci

Info

Publication number: CA2135748A1
Authority: CA; Canada
Prior art keywords: antigen; age; epitope; modified; compound
Prior art date: 1992-05-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2135748

Other languages

English (en)

Inventor

Anthony Cerami

Helen Vlassara

Richard J. Bucala

Edward Y. Skolnik

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Rockefeller University

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-15

Filing date

1993-05-17

Publication date

1993-11-25

1993-05-17 Application filed by Individual filed Critical Individual

1993-11-25 Publication of CA2135748A1 publication Critical patent/CA2135748A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 67
230000028993 immune response Effects 0.000 title claims description 28
239000000427 antigen Substances 0.000 claims abstract description 220
108091007433 antigens Proteins 0.000 claims abstract description 208
102000036639 antigens Human genes 0.000 claims abstract description 208
150000001875 compounds Chemical class 0.000 claims abstract description 70
238000006243 chemical reaction Methods 0.000 claims abstract description 38
238000011282 treatment Methods 0.000 claims abstract description 17
230000030741 antigen processing and presentation Effects 0.000 claims abstract description 16
108010005094 Advanced Glycation End Products Proteins 0.000 claims description 99
210000001744 T-lymphocyte Anatomy 0.000 claims description 62
108090000765 processed proteins & peptides Proteins 0.000 claims description 59
108090000623 proteins and genes Proteins 0.000 claims description 50
102000004169 proteins and genes Human genes 0.000 claims description 48
230000002163 immunogen Effects 0.000 claims description 44
102000004196 processed proteins & peptides Human genes 0.000 claims description 44
210000004027 cell Anatomy 0.000 claims description 43
229920001184 polypeptide Polymers 0.000 claims description 40
210000000612 antigen-presenting cell Anatomy 0.000 claims description 34
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 32
239000004472 Lysine Substances 0.000 claims description 32
238000009739 binding Methods 0.000 claims description 28
230000027455 binding Effects 0.000 claims description 27
210000002540 macrophage Anatomy 0.000 claims description 26
239000007795 chemical reaction product Substances 0.000 claims description 22
210000000987 immune system Anatomy 0.000 claims description 22
230000000890 antigenic effect Effects 0.000 claims description 20
241000124008 Mammalia Species 0.000 claims description 14
206010028980 Neoplasm Diseases 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 12
208000015181 infectious disease Diseases 0.000 claims description 9
239000003446 ligand Substances 0.000 claims description 9
208000023275 Autoimmune disease Diseases 0.000 claims description 8
208000035473 Communicable disease Diseases 0.000 claims description 7
201000011510 cancer Diseases 0.000 claims description 7
230000005847 immunogenicity Effects 0.000 claims description 6
230000037452 priming Effects 0.000 claims description 6
108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 4
238000009877 rendering Methods 0.000 claims description 4
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 4
102000004127 Cytokines Human genes 0.000 claims description 3
108090000695 Cytokines Proteins 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
239000000203 mixture Substances 0.000 claims description 2
230000009870 specific binding Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 2
230000001939 inductive effect Effects 0.000 claims 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
235000018417 cysteine Nutrition 0.000 claims 1
238000003306 harvesting Methods 0.000 claims 1
235000018102 proteins Nutrition 0.000 claims 1
230000004614 tumor growth Effects 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 abstract description 12
230000007246 mechanism Effects 0.000 abstract description 12
238000003556 assay Methods 0.000 abstract description 11
230000002708 enhancing effect Effects 0.000 abstract description 4
238000001994 activation Methods 0.000 abstract 1
102000006382 Ribonucleases Human genes 0.000 description 61
108010083644 Ribonucleases Proteins 0.000 description 61
VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 21
210000004408 hybridoma Anatomy 0.000 description 21
230000004044 response Effects 0.000 description 21
101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 20
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 20
239000003795 chemical substances by application Substances 0.000 description 19
238000012986 modification Methods 0.000 description 18
NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 17
239000012634 fragment Substances 0.000 description 16
230000000638 stimulation Effects 0.000 description 16
239000008103 glucose Substances 0.000 description 15
235000000346 sugar Nutrition 0.000 description 14
230000001965 increasing effect Effects 0.000 description 13
230000004048 modification Effects 0.000 description 13
108020003175 receptors Proteins 0.000 description 13
102000005962 receptors Human genes 0.000 description 13
229940045189 glucose-6-phosphate Drugs 0.000 description 12
238000011534 incubation Methods 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 11
238000000338 in vitro Methods 0.000 description 11
230000009257 reactivity Effects 0.000 description 11
238000013467 fragmentation Methods 0.000 description 10
238000006062 fragmentation reaction Methods 0.000 description 10
239000000047 product Substances 0.000 description 10
150000008163 sugars Chemical class 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
229940024606 amino acid Drugs 0.000 description 9
125000004432 carbon atom Chemical group C* 0.000 description 9
229940088598 enzyme Drugs 0.000 description 9
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
238000012545 processing Methods 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
238000002965 ELISA Methods 0.000 description 8
102000001554 Hemoglobins Human genes 0.000 description 8
108010054147 Hemoglobins Proteins 0.000 description 8
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
230000006870 function Effects 0.000 description 8
238000006206 glycosylation reaction Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
238000007792 addition Methods 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
230000013595 glycosylation Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
230000017854 proteolysis Effects 0.000 description 7
108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
229910052739 hydrogen Inorganic materials 0.000 description 6
239000001257 hydrogen Substances 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
241000283690 Bos taurus Species 0.000 description 5
230000003302 anti-idiotype Effects 0.000 description 5
125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
239000000463 material Substances 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000002285 radioactive effect Effects 0.000 description 5
229940104230 thymidine Drugs 0.000 description 5
241000283707 Capra Species 0.000 description 4
241000511343 Chondrostoma nasus Species 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
102000000588 Interleukin-2 Human genes 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
239000004365 Protease Substances 0.000 description 4
241000700605 Viruses Species 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000008569 process Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
238000005406 washing Methods 0.000 description 4
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
102000018832 Cytochromes Human genes 0.000 description 3
108010052832 Cytochromes Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229930040373 Paraformaldehyde Natural products 0.000 description 3
102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 description 3
108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 3
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229920002866 paraformaldehyde Polymers 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000012279 sodium borohydride Substances 0.000 description 3
229910000033 sodium borohydride Inorganic materials 0.000 description 3
230000004936 stimulating effect Effects 0.000 description 3
230000001629 suppression Effects 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
239000013598 vector Substances 0.000 description 3
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
238000011752 CBA/J (JAX™ mouse strain) Methods 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
239000004366 Glucose oxidase Substances 0.000 description 2
108010015776 Glucose oxidase Proteins 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
102000007079 Peptide Fragments Human genes 0.000 description 2
108010033276 Peptide Fragments Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
239000000556 agonist Substances 0.000 description 2
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000003190 augmentative effect Effects 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000010367 cloning Methods 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000007071 enzymatic hydrolysis Effects 0.000 description 2
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
102000054766 genetic haplotypes Human genes 0.000 description 2
229940116332 glucose oxidase Drugs 0.000 description 2
235000019420 glucose oxidase Nutrition 0.000 description 2
125000005842 heteroatom Chemical group 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
-1 hydroxyethyl group Chemical group 0.000 description 2
150000002466 imines Chemical class 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000002372 labelling Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
210000003024 peritoneal macrophage Anatomy 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
230000008707 rearrangement Effects 0.000 description 2
230000000284 resting effect Effects 0.000 description 2
239000002356 single layer Substances 0.000 description 2
241000894007 species Species 0.000 description 2
238000001890 transfection Methods 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
RGZSQWQPBWRIAQ-HUUCEWRRSA-N (2r)-6-methyl-2-[(1s)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-ol Chemical compound CC(C)=CCC[C@@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-HUUCEWRRSA-N 0.000 description 1
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
238000010600 3H thymidine incorporation assay Methods 0.000 description 1
BWRRWBIBNBVHQF-UHFFFAOYSA-N 4-(3-pyridin-2-yl-1,2,4-oxadiazol-5-yl)butanoic acid Chemical compound O1C(CCCC(=O)O)=NC(C=2N=CC=CC=2)=N1 BWRRWBIBNBVHQF-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
238000003691 Amadori rearrangement reaction Methods 0.000 description 1
101150020229 Apcs gene Proteins 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010077805 Bacterial Proteins Proteins 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
241000736839 Chara Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
101710204837 Envelope small membrane protein Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010087819 Fc receptors Proteins 0.000 description 1
102000009109 Fc receptors Human genes 0.000 description 1
239000012029 Fehling's reagent Substances 0.000 description 1
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
241001669573 Galeorhinus galeus Species 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
102000005548 Hexokinase Human genes 0.000 description 1
108700040460 Hexokinases Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
241000186781 Listeria Species 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
101710145006 Lysis protein Proteins 0.000 description 1
241000867077 Macropes Species 0.000 description 1
241000343235 Maso Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
101100079509 Oncidium hybrid cultivar NCED gene Proteins 0.000 description 1
102000003840 Opioid Receptors Human genes 0.000 description 1
108090000137 Opioid Receptors Proteins 0.000 description 1
108010058846 Ovalbumin Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 1
102000001105 Phosphofructokinases Human genes 0.000 description 1
108010069341 Phosphofructokinases Proteins 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
101710192189 Ribonuclease 1 Proteins 0.000 description 1
102100039832 Ribonuclease pancreatic Human genes 0.000 description 1
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241001611093 Stimula Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
230000006052 T cell proliferation Effects 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
239000012031 Tollens' reagent Substances 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
229940102884 adrenalin Drugs 0.000 description 1
108010055267 advanced glycation end products-bovine serum albumin Proteins 0.000 description 1
108010066167 advanced glycation end products-human serum albumin Proteins 0.000 description 1
VFRROHXSMXFLSN-KCDKBNATSA-N aldehydo-D-galactose 6-phosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O VFRROHXSMXFLSN-KCDKBNATSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
125000006294 amino alkylene group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
210000000628 antibody-producing cell Anatomy 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
JPIYZTWMUGTEHX-UHFFFAOYSA-N auramine O free base Chemical compound C1=CC(N(C)C)=CC=C1C(=N)C1=CC=C(N(C)C)C=C1 JPIYZTWMUGTEHX-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000019771 cognition Effects 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
108010047295 complement receptors Proteins 0.000 description 1
102000006834 complement receptors Human genes 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
125000005442 diisocyanate group Chemical group 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000002557 fixed macrophage Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000005021 gait Effects 0.000 description 1
229960000587 glutaral Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000002429 hydrazines Chemical class 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
230000008073 immune recognition Effects 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000004073 interleukin-2 production Effects 0.000 description 1
150000002540 isothiocyanates Chemical class 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000023837 negative regulation of proteolysis Effects 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
230000000771 oncological effect Effects 0.000 description 1
230000014207 opsonization Effects 0.000 description 1
229940092253 ovalbumin Drugs 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229930029653 phosphoenolpyruvate Natural products 0.000 description 1
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
238000007747 plating Methods 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000008685 targeting Effects 0.000 description 1
101150019895 thiE gene Proteins 0.000 description 1
SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000008427 tissue turnover Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Physics & Mathematics (AREA)
Public Health (AREA)
Pathology (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Gastroenterology & Hepatology (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Veterinary Medicine (AREA)
Analytical Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physiology (AREA)
Virology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

CA 2135748 1992-05-15 1993-05-17 Methodes et agents servant a la modulation de la reaction immunitaire, et utilisation de ceux-ci Abandoned CA2135748A1 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US88355592A	1992-05-15	1992-05-15
US07/883,555		1992-05-15
US88699192A	1992-05-21	1992-05-21
US07/886,991		1992-05-21

Publications (1)

Publication Number	Publication Date
CA2135748A1 true CA2135748A1 (fr)	1993-11-25

Family

ID=27128695

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2135748 Abandoned CA2135748A1 (fr)	1992-05-15	1993-05-17	Methodes et agents servant a la modulation de la reaction immunitaire, et utilisation de ceux-ci

Country Status (5)

Country	Link
EP (1)	EP0641220A1 (fr)
JP (1)	JPH07508287A (fr)
AU (1)	AU4250393A (fr)
CA (1)	CA2135748A1 (fr)
WO (1)	WO1993023081A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6410598B1 (en)	1994-02-03	2002-06-25	Michael P. Vitek	Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
CA2182731A1 (fr) *	1994-02-03	1995-08-10	Michael P. Vitek	Compositions et procedes de modulation de l'amyloidose induite par des produits terminaux de glycosylation avancee
CA2248192A1 (fr) *	1996-03-12	1997-09-18	Picower Institute For Medical Research	Traitement de l'infection a vih par action sur le recepteur de la cyclophiline de cellules hotes
US20030118630A1 (en) *	2001-12-07	2003-06-26	Anthony Cerami	Immune modulation device for use in animals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU600306B2 (en) *	1986-09-12	1990-08-09	Rockefeller University, The	Methods and agents for removing advanced glycosylation endproducts

1993
- 1993-05-17 AU AU42503/93A patent/AU4250393A/en not_active Abandoned
- 1993-05-17 EP EP93911328A patent/EP0641220A1/fr not_active Withdrawn
- 1993-05-17 JP JP6503774A patent/JPH07508287A/ja active Pending
- 1993-05-17 WO PCT/US1993/004624 patent/WO1993023081A1/fr not_active Ceased
- 1993-05-17 CA CA 2135748 patent/CA2135748A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
WO1993023081A1 (fr)	1993-11-25
EP0641220A1 (fr)	1995-03-08
JPH07508287A (ja)	1995-09-14
AU4250393A (en)	1993-12-13

Publication	Publication Date	Title
Chesnut et al.	1980	Antigen recognition by T cells and B cells: recognition of cross-reactivity between native and denatured forms of globular antigens
US6403092B1 (en)	2002-06-11	Immune response modulator alpha-2 macroglobulin complex
JP2000055916A (ja)	2000-02-25	インスリン依存性糖尿病の診断と治療
JPS61501705A (ja)	1986-08-14	Ｔ細胞及びｂ細胞決定基の両者を含む合成ｂ型肝炎ウイルスワクチン
EA010506B1 (ru)	2008-10-30	Способы, наборы и композиции для разработки и применения моноклональных антител, специфичных к антигенам с низкой иммуногенностью
Atassi et al.	1984	A novel approach for localization of the continuous protein antigenic sites by comprehensive synthetic surface scanning: antibody and T-cell activity to several influenza hemagglutinin synthetic sites
JPH02500004A (ja)	1990-01-11	非還元・非酵素的糖鎖形成蛋白に対するモノクローナル抗体
Ferguson et al.	1983	Immunoregulatory properties of antigenic fragments from bovine serum albumin
Tite et al.	1987	Inverse Ir gene control of the antibody and T cell proliferative responses to human basement membrane collagen.
JPS60155133A (ja)	1985-08-15	アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
CA2135748A1 (fr)	1993-11-25	Methodes et agents servant a la modulation de la reaction immunitaire, et utilisation de ceux-ci
Anders et al.	1979	In vitro antibody response to influenza virus: I. T cell dependence of secondary response to hemagglutinin
JPH04505401A (ja)	1992-09-24	主要組織適合抗原に会合したペプチドを認識するモノクローナル抗体
NZ241368A (en)	1994-03-25	Fibroblast growth factor receptor blocking peptides and their use in diagnostic methods and test kits
CA2188582A1 (fr)	1995-11-30	Method et reactifs pour le traitement de l'arthrite rhumatoide
JPH06511151A (ja)	1994-12-15	アルコール中毒患者を同定しアルコール消費を監視するためのイムノアッセイ
AU726344B2 (en)	2000-11-02	High fluorescence specific immune enhancing factor and methods of use for same
AU754988B2 (en)	2002-11-28	Immune response modulator alpha-2 macroglobulin complex
Nair et al.	2013	Optimized fluorescent labeling to identify memory B cells specific for Neisseria meningitidis serogroup B vaccine antigens ex vivo
Peterson et al.	1983	Functional differentiation in the genetic control of murine T lymphocyte responses to human fibrinopeptide B.
US20220275049A1 (en)	2022-09-01	Antigenic polypeptides and methods of use thereof
JP2022542119A (ja)	2022-09-29	抗原性ポリペプチドおよびその使用方法
Ruffilli et al.	1970	Repression of the synthesis of immunoglobulins in newborn mice by antibodies directed against the variable region of light chains
JP2002543091A (ja)	2002-12-17	インターロイキン１２に由来するペプチドホモダイマーおよびペプチドヘテロダイマー
JPH0746105B2 (ja)	1995-05-17	インタ−フエロン−γの免疫化学的測定法および測定用試薬

Legal Events

Date	Code	Title	Description
2001-05-17	FZDE	Dead